Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 3/20 | 0.57 |
| ▸ | CCND1 | P24385 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20882095 | 0.85 | GPX4 (0.77) | GPX4HDAC6HDAC1TRPV1FAAH | |
| SCHEMBL20018759 | 0.85 | GPX4 (1.00) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL5556447 | 0.85 | GPX4 (0.77) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL8320157 | 0.84 | HDAC6 (0.74) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL18688569 | 0.83 | HDAC6 (0.77) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL20817603 | 0.82 | HDAC6 (0.76) | GPX4HDAC6HDAC1TRPV1FAAH | |
| SCHEMBL8252701 | 0.82 | HDAC6 (1.00) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL30562026 | 0.82 | GPX4 (0.65) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL28918979 | 0.82 | GPX4 (0.68) | GPX4HDAC6HDAC1TAAR1TRPV1 | |
| SCHEMBL969392 | 0.81 | TRPV1 (0.72) | GPX4HDAC6HDAC1TRPV1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GLOBAVIR BIOSCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016201354-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GLOBAVIR BIOSCIENCES, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361298-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | IDO2, IDO1, TDO2 | GPX4 324/4885HDAC6 25/4885HDAC1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.